CN100345554C - Compounding medicinal capsule for treating angiitis - Google Patents
Compounding medicinal capsule for treating angiitis Download PDFInfo
- Publication number
- CN100345554C CN100345554C CNB200510040918XA CN200510040918A CN100345554C CN 100345554 C CN100345554 C CN 100345554C CN B200510040918X A CNB200510040918X A CN B200510040918XA CN 200510040918 A CN200510040918 A CN 200510040918A CN 100345554 C CN100345554 C CN 100345554C
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- powder
- fine powder
- angelicae sinensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a Chinese and western medicine compound capsule for treating angitis. 3 to 10 portions of ginseng, 10 to 40 portions of achyranthes roots, 20 to 40 portions of angelica and 10 to 40 of hemlock parsley are used as raw materials. After affective ingredients are decocted with water and extracted, the affective ingredients are mixed with daily dose of 190 to 570 mg of aspirin, 30 to 110 mg of oryzanol, 40 to 150 mg of rutin, 120 to 400 mg of VC, 20 to 50 mg of dibazole, 220 to 700 mg of glucurolactone, 6 to 19 mg of anisodamine; then, the mixture is pulverized into fine powder to be encapsulated, and the finished product medicine is made. Through clinical verification, the present invention has the advantages of treating both manifestation and root causes of disease, not relapsing after cure, etc. The effective rate is as high as 100%; toxic and side effects do not exist. The medicine of the present invention is suitable for treating angitis and deep vein barrage, and also has quite therapeutic effect on cerebral blood vessel rigidification.
Description
Technical field
The present invention relates to a kind of medicine, specifically be meant a kind of medicine for the treatment of thromboangiitis obliterans.
Background technology
Thromboangiitis obliterans claims thromboangiitis obliterans again, is called for short vasculitis, is one of dangerous disease of surgery of Chinese medicine.Its cause of disease is still not exclusively to understand so far.Mostly the patient is that person between twenty and fifty, the overwhelming majority are the male.
The method of treatment thromboangiitis obliterans is roughly as follows at present:
1, doctor trained in Western medicine: Drug therapy: for the patient of first and second phase based on vasodilator, as parathyrine E (PGE) and α receptor blocking agent, beta receptor analeptic: scoline, benzazoline etc. in the change.Be aided with broad ectrum antibiotic and analgesic again.Can obtain certain curative effect.And only can give potent analgesic for the patient of the third phase, do not play the medicine of therapeutical effect.Operative treatment: (1), sympathectomy: only the part patient for first and second phase can obtain short-term effect.(2), artery reconstruction art: the small number of patients that is only applicable to tremulous pulse trunk office section obturation.(3), free vessel pedicle omentum grafting: operating difficulty is big, and the patient suffering is big, and trouble limb functional rehabilitation is not good enough.(4), arteriovenous shunt by stages: patient suffering's great achievement power is low, and some underlying issue remains further investigation.(5), amputation: the patient for the third phase only can adopt this kind operation at present, stays deformity to the patient.
2, the traditional Chinese medical science: 1, cloudy plug type: add and subtract with YANGHE TANG; (2), damp-heat type: add flavor or Herba Artemisiae Scopariae Semen Phaseoli vapour plus-minus with SIMIAOYONGAN TANG; (3) heat-toxin type: with the SIMIAOYONGAN TANG plus-minus, to get its heat-clearing and toxic substances removing, the merit of blood circulation promoting and blood stasis dispelling is difficult to cure but clinical treatment is but only got better; (4) both Qi and blood deficiency: Tonga subtracts with the Gu step.Above-mentioned decoction is played a role to this condition of disease, but effect is unsatisfactory, be difficult to effect a radical cure fully, and easily recurrence.
Summary of the invention
The purpose of this invention is to provide a kind of medicament capsule with the bonded treatment thromboangiitis obliterans of Chinese medicine and western medicine, it can fundamentally solve patient's misery, make the systolic and diastolic function of small artery autonomy recover normal by the vegetative nerve of regulating limb vessel, the ischemic region blood circulation is improved, reach the purpose of radical cure thromboangiitis obliterans.
The present invention realizes with following technical scheme: the vasculitic compound capsule of a kind of treatment, it is characterized in that Radix Ginseng is worn into fine powder, with Radix Cyathulae, Radix Angelicae Sinensis, Rhizoma Chuanxiong four flavor raw material of Chinese medicine after decocting extracts and Western medicine make, wherein the weight portion of each crude drug of Chinese medicine is:
Radix Ginseng 3-10 part Radix Cyathulae 10-40 part
Radix Angelicae Sinensis 20-40 part Rhizoma Chuanxiong 10-40 part
Dosage every day of every kind of medicine of Western medicine is:
Aspirin 190-630mg oryzanol 30-110mg
Rutin 40-150mg VC 120-400mg
Bendazol 20-50mg Glucuronic acid lactone 220-700mg
Anisodamine 6-19mg
Each crude drug of the present invention and consumption thereof be the inventor carry out a large amount of clinical grope to sum up draw, each raw material consumption all has better curative effect in above-mentioned scope.
The preparation method of medicine of the present invention is as follows:
1) take by weighing various material medicines in proportion, standby;
2) Radix Ginseng powder is broken into fine powder, standby;
3) Radix Cyathulae, Radix Angelicae Sinensis, Rhizoma Chuanxiong three flavor Chinese medicines are decocted with water secondary, decocted 1-1.5 hour at every turn, slagging-off gets filtrate;
4) merge secondary filtrate, be concentrated into the clear paste of relative density about 1.30 (50 ℃ of surveys);
5) the Radix Ginseng fine powder is added mixing in the clear paste, and add appropriate amount of starch;
6) powder during crushed after being dried becomes;
7) middle powder adding aspirin, oryzanol, rutin, VC, bendazol, Glucuronic acid lactone, Anisodamine mixed grinding are crossed 100 mesh sieves;
8) medicated powder is packed into Capsules gets finished product.
Medicine of the present invention wherein Chinese medicine Radix Ginseng, Radix Angelicae Sinensis have enrich blood, inrigorating qi and promoting blood circulation promotes the production of body fluid Rhizoma Chuanxiong, Radix Cyathulae: have promoting blood circulation and stopping pain, the dampness removing that stimulates the menstrual flow is regulated descending effect.Effect with inrigorating qi and promoting blood circulation; that aspirin in the Western medicine has is analgesic, analgesia, antiinflammatory, anticoagulant effect; it is synthetic that prolonged application also can suppress the liver thrombinogen, and Glucuronic acid lactone is an important detoxifcation material in the body, and the liver protecting and Detoxication are arranged.Oryzanol, rutin, VC, Anisodamine and bendazol, have the vegetative nerve of regulating limb vessel and make the systolic and diastolic function of small artery autonomy recover normal, keep blood vessel elasticity, reduce its fragility, improve the ischemic region blood circulation, thereby reach " mark ", " basis " double purpose of controlling.
The specific embodiment
Below in conjunction with embodiment and further auspicious using method of the present invention and the effect stated of experimental example.
Embodiment 1
The raw material prescription:
Radix Ginseng 30g Radix Cyathulae 400g
Radix Angelicae Sinensis 500g Rhizoma Chuanxiong 400g
Aspirin 63g oryzanol 11g
Rutin 13.8g VC 35g
Bendazol 5.5g Glucuronic acid lactone 70g
Anisodamine 2.1mg
Preparation method:
The Radix Ginseng powder is broken into fine powder; Radix Cyathulae, Radix Angelicae Sinensis, Rhizoma Chuanxiong are merged the water decocting method to be extracted 2 times, the each decoction 1-1.5 hour, after the slagging-off with twice filtrate complete and after be concentrated into the clear paste of relative density about 1.30, the Radix Ginseng fine powder is added in the clear paste mixing and adds appropriate amount of starch, mix equal after drying; The grain weight amount was 399.6g during crushed after being dried became; Aspirin, oryzanol, rutin, VC, bendazol, Glucuronic acid lactone, Anisodamine and Chinese medicine powder mixed grinding are crossed 100 mesh sieves, in the Capsules of packing into.By every capsules medicated powder 0.60g that packs into, can prepare 1000 of capsules.
Test example: the vasculitic clinical observation of Drug therapy of the present invention.
1, physical data:
To control clinical patients 150 examples, wherein two lower limb vasculitiss account for 85%, and the upper limb vasculitis accounts for 15%, and the course of disease is the shortest 6 months, and the longest 27 years, simple ulcer accounts for 30%, and the lower limb gangrene accounts for 15%; Age of onset 20-40 year.
2, diagnostic criteria:
As follows according to the diagnostic criteria that CAIM (Chinese Association Of Integrative Medicine) peripheral vascular disease Professional Committee works out nineteen ninety-five:
1) mostly is the male, age of onset 20-40 year.
2) performance of chronic limb artery ischemic is arranged: send out cool, be afraid of cold, numbness, intermittent limping, congestion, malnutrition change etc., often involve lower limb, it is few that upper limb is sent out the patient.
3) 40%-60% has migration row superficial thrombophlebitis medical history and sign.
4) various Inspection Certificates, limb artery is narrow, inaccessible position Duo Zai popliteal tremulous pulse and distal artery thereof (often involve in the limbs, small artery).
5) smoking history is almost arranged entirely, or catch cold and freeze history.
6) in the disease activity phase, IgG, IgA, the anti-tremulous pulse antibody of IgM in the blood samples of patients, the immune complex positive rate increases, and the T cell function reduces.
7) angiography: pathological changes is many, and tremulous pulse is segmental obturation, narrow at thigh, popliteal tremulous pulse and distal artery thereof, and the many genus of tremulous pulse between the inaccessible section and proximal part tremulous pulse are normal, and arterial occlusive nearly far-end has tree root shape side Zhi Xunhuan tremulous pulse more.
3, Therapeutic Method:
Oral capsule 0.6g/ grain of the present invention, every day 3 times, each 2-3 grain, 1 month is a course of treatment.General treatment 6-8 course of treatment.
4, criterion of therapeutical effect:
Cure: cardinal symptom disappears, wound healing.
Produce effects: sx, wound dwindle, blood samples of patients circulatory disturbance has improvement, still need treat.
Invalid: the treatment more than two months sings and symptoms do not have obvious change.
5, therapeutic effect
Cure 146 routine cure rates 97.3%
Produce effects 4 routine obvious effective rates 2.7%
Invalid 0 routine inefficiency 0%
Claims (2)
1, the vasculitic compound capsule of a kind of treatment is characterized in that Radix Ginseng wears into fine powder, with Radix Cyathulae, Radix Angelicae Sinensis, Rhizoma Chuanxiong three flavor raw material of Chinese medicine after decocting extracts and Western medicine make, wherein the weight portion of each crude drug of Chinese medicine is:
Radix Ginseng 3-10 part Radix Cyathulae 10-40 part
Radix Angelicae Sinensis 20-40 part Rhizoma Chuanxiong 10-40 part
Dosage every day of every kind of medicine of Western medicine is:
Aspirin 190-630mg oryzanol 30-110mg
Rutin 40-150mg VC 120-400mg
Bendazol 20-50mg Glucuronic acid lactone 220-700mg
Anisodamine 6-19mg.
2, the described a kind of preparation method for the treatment of vasculitic compound capsule of claim 1 is characterized in that carrying out as follows:
1) take by weighing various material medicines in proportion, standby;
2) Radix Ginseng powder is broken into fine powder, standby;
3) Radix Cyathulae, Radix Angelicae Sinensis, Rhizoma Chuanxiong three flavor Chinese medicines are decocted with water secondary, decocted 1-1.5 hour at every turn, slagging-off gets filtrate;
4) merge secondary filtrate, measure the clear paste that is concentrated into relative density about 1.30 down at 50 ℃;
5) the Radix Ginseng fine powder is added mixing in the clear paste, and add appropriate amount of starch;
6) powder during crushed after being dried becomes;
7) middle powder adding aspirin, oryzanol, rutin, VC, bendazol, Glucuronic acid lactone, Anisodamine mixed grinding are crossed 100 mesh sieves;
8) Capsules of packing into gets finished product.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510040918XA CN100345554C (en) | 2005-07-04 | 2005-07-04 | Compounding medicinal capsule for treating angiitis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510040918XA CN100345554C (en) | 2005-07-04 | 2005-07-04 | Compounding medicinal capsule for treating angiitis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1723972A CN1723972A (en) | 2006-01-25 |
CN100345554C true CN100345554C (en) | 2007-10-31 |
Family
ID=35923689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200510040918XA Expired - Fee Related CN100345554C (en) | 2005-07-04 | 2005-07-04 | Compounding medicinal capsule for treating angiitis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100345554C (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108619364A (en) * | 2018-08-01 | 2018-10-09 | 李伟 | A kind of drug and preparation method thereof for treating diabetes vasculitis disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1224614A (en) * | 1998-01-24 | 1999-08-04 | 倪德贵 | Medicine for preventing and curing cardiac and cerebral vascular diseases and its preparation |
-
2005
- 2005-07-04 CN CNB200510040918XA patent/CN100345554C/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1224614A (en) * | 1998-01-24 | 1999-08-04 | 倪德贵 | Medicine for preventing and curing cardiac and cerebral vascular diseases and its preparation |
Also Published As
Publication number | Publication date |
---|---|
CN1723972A (en) | 2006-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1476849A (en) | Medicine composition for promoting blood circulation and removing stasis | |
CN1091609C (en) | Tincture for treating rheumatoid arthritis and its preparing process | |
CN1232266C (en) | Chinese medicinal capsules for apoplexy and thoracic palsy and preparation thereof | |
CN1117582C (en) | medicine for treating rheumatoid arthritis and preparing process thereof | |
CN100345554C (en) | Compounding medicinal capsule for treating angiitis | |
CN101032604A (en) | Chinese medicine preparation for curing vascular type headache | |
CN1159030C (en) | Capsule 'Jingmaitong' | |
CN1843421A (en) | Rheumatoid disease treating medicine | |
CN102198181B (en) | Antithrombotic and thrombosis-eliminating preparation | |
CN1186065C (en) | Externally applied medicinal stasis-and swelling-eliminating powder for treating chronic pelvic inflammation | |
CN1947791A (en) | External use traditional Chinese medicine ointment for treating heart diseases | |
CN1879783A (en) | A medicine for treating diabetes | |
CN103585414B (en) | Pharmaceutical composition for treating sciatica and osteoporosis | |
CN1241603C (en) | Bone joint disease capsule and its manufacturing metod | |
CN106214828A (en) | A kind of Chinese medicine of passage, nourishing blood and preparation method thereof | |
CN1176690C (en) | Medicine for treating chronic nephritis | |
CN1709400A (en) | Medicine for treating ulcer haemorrhage | |
CN1246027C (en) | Medicine for treating high blood pressure and its preparation method | |
CN1279951C (en) | Pure Chinese traditional medicine capsule for treating hyperthyroidism and simple goiter | |
CN1238013C (en) | Myocarditis treating Chinese medicine prepn | |
CN1076622C (en) | Chinese medicine for curing nephritis | |
CN1115160C (en) | Orally-applied medicine for treating hyperosteogeny | |
CN104623368A (en) | Decoction medicine for treating chronic glomerulonephritis and preparation method thereof | |
CN1435217A (en) | Bone-strengthening medicine and producing method thereof | |
CN113713078A (en) | Traditional Chinese medicine formula for treating diabetes mellitus with peripheral neuropathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071031 Termination date: 20100704 |